Pharmacogenomics and sepsis-induced renal failure: Effects of β2-adrenoceptor function on the course of sepsis

Current Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 2, 2008, Pages 98-107

  Nakamura, Akio ^a   Yanagawa, Yukishige ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; DOPEXAMINE; ENDOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; DNA SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTOXEMIA; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HAPLOTYPE; HUMAN; HYPOTENSION; INFECTION RISK; KIDNEY DISEASE; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; NONVIRAL GENE THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM;

NEGIBACTERIA;

EID: 65949103560     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692110806020098     Document Type: Review

References (132)

1. Ader, R.; Cohen, N. and Felten, D. (1995) Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet 345, 99-103.
2. Agnese, D. M.; Calvano, J. E.; Hahm, S. J.; Coyle, S. M.; Corbett, S. A.; Calvano, S. E. and Lowry, S. F. (2002) Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J. Infect. Dis. 186, 1522-1525.
3. Begany, D. P.; Carcillo, J. A.; Herzer, W. A.; Mi, Z. and Jackson, E. K. (1996) Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J. Pharmacol. Exp. Ther. 278, 37-41.
4. Bergquist, J.; Tarkowski, A.; Ekman, R. and Ewing, A. (1994) Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc. Natl. Acad. Sci. USA 91, 12912-12916.
5. Bernard, G. R.; Vincent, J. L. and Laterre, P. F. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709.
6. 2- adrenergic receptor-dependent and - independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. Intensive Care Med. 24, 1315-1322.
7. 2-adrenergic receptor. J. Mol. Cell Cardiol. 29, 961-967.
8. Boim, M. A.; dos Santos, O. F.; Barros, E. J. and Schor, N. (1997) Glomerular hemodynamics in acute renal failure. Ren. Fail. 19, 209-212.
9. Bone, R. C.; Balk, R. A.; Cerra, F. B.; Dellinger, R. P.; Fein, A. M.; Knaus, W. A.; Schein, R. M. and Sibbald, W. J. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101, 1644-1655.
10. Bone, R. C. and Newton, I. (1996) SEPSIS, SIRS, and CARS. Crit. Care Med. 24, 1125-1128.
11. Bonventre, J. V. and Weinberg, J. M. (2003) Recent advances in the pathophysiology of ischemic acute renal failure. J. Am. Soc. Nephrol. 14, 2199-210.
12. 2-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 101, 2877-2882.
13. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol. Pharmacol. 35, 295-303.
14. 2-adrenergic receptors in rat kidney. Kidney Int. 59, 515-531.
15. Butchers, P. R.; Vardey, C. J. and Johnson, M. (1991) Salmeterol: A potent and long-acting inhibitor of inflammatory mediator release from human lung. Br. J. Pharmacol. 104, 672-676.
16. Camussi, G.; Ronco, C.; Montrucchio, G. and Piccoli, G. (1998) Role of soluble mediators in sepsis and renal failure. Kidney Int. 53, S38-S42.
17. Casey, L. C.; Balk, R. A. and Bone, R. C. (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119, 771-778.
18. Child, N. J.; Yang, I. A.; Pulletz, M. C.; de Courcy-Golder, K.; Andrews, A. L.; Pappachan, V. J. and Holloway, J. W. (2003) Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem. Soc. Trans. 31, 652-653.
19. 2-adrenergic receptor gene. J. Biol. Chem. 274, 16694-16700.
20. Collins, F. S. (1999) Shattuck lecture: medical and societal consequences of the Human Genome Project. N. Engl. J. Med. 341, 28-37.
21. Crawley, E.; Kay, R.; Sillibourne, J.; Patel, P.; Hutchinson, I. and Woo, P. (1999) Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 42, 1101-1108.
22. Cunningham, P. N.; Dyanov, H. M.; Park, P.; Wang, J.; Newell, K. A. and Quigg, R. J. (2002) Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J. Immunol. 168, 5817-5823.
23. 2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J. Allergy Clin. Immunol. 100, 261-265.
24. DiBona, G. F. and Kopp, U. C. (1997) Neural control of renal function. Physiol. Rev. 77, 75-197.
25. Dinarello, C. A. (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77, 1627-1652.
26. 2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030-1035.
27. Emilien, G. and Maloteaux, J. -M. (1998) Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur. J. Clin. Pharmacol. 53, 389-404.
28. Fang, X. M.; Schroder, S.; Hoeft, A. and Stuber, F. (1999) Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit. Care Med. 27, 1330-1334.
29. Fekete, A.; Treszl, A.; Toth-Heyn, P.; Vannay, A.; Tordai, A.; Tulassay, T. and Vasarhelyi, B. (2003) Association between heat shock protein 72 gene polymorphism and acute renal failure in premature neonates. Pediatr. Res. 54, 452-455.
30. Fishman, D.; Faulds, G.; Jeffery, R.; Mohamed-Ali, V.; Yudkin, J. S. and Humphries, S. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102, 1369-1376.
31. Flo, T. H.; Halaas, O.; Torp, S.; Ryan, L.; Lien, E.; Dybdahl, B.; Sundan, A. and Espevik, T. (2001) Differential expression of Toll-like receptor 2 in human cells. J. Leukoc. Biol. 69, 474-481.
32. Fong, J. S.; De Chadarevian, J.P. and Kaplan, B.S. (1982) Hemolytic Uremic Syndrome. Current concepts and management. Pediatr. Clin. N. Am. 29, 835-856.
33. Fougueray, B.; Philipp, C.; Herbelin, A.; Perez, J.; Ardaillov, R. and Baud, L. (1993) Cytokine formation within rat glomeruli during experimental endotoxaemia. J. Am. Soc. Nephrol. 3, 1783-1791.
34. 2-adrenergic receptors in large arteries. J. Mol. Cell Cardiol. 30, 1037-1045.
35. 2-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J. Physiol. 546, 583-589.
36. Gibot, S.; Cariou, A.; Drouet, L.; Rossignol, M. and Ripoll, L. (2002) Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit. Care Med. 30, 969-973.
37. Gluser, M. P.; Zanetti, G.; Baumgartner, J. -D. and Cohen, J. (1991) Septic shock: pathogenesis. Lancet 338, 732-736.
38. 2-adrenergic receptors increases gain of excitation-contraction coupling in mouse ventricular myocytes. Am. J. Physiol. 287, H1029-H1038.
39. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268, 23116-23121.
40. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13, 25-33.
41. Guan, Z.; Miller, S. B. and Greenwald, J. E. (1995) Zaprinast accelerates recovery from established acute renal failure in the rat. Kidney Int. 47, 1569-1575.
42. 2-Adrenoceptor polymorphisms: are they clinically important?, Thorax 51, 351-353.
43. 2-adrenoceptor stimulant. Part II. Effects on the peripheral organs (author's translation). Nippon Yakurigaku Zasshi 75, 333-64. (Japanese)
44. Hetier, P.; Ayala, J.; Bousseau, A. and Prochiantz, A. (1991) Modulation of interleukin-1 and tumor necrosis factor expression by β-adrenergic agonists in mouse ameboid microgial cells. Exp. Brain Res. 86, 407-413.
45. Holmes, C. L.; Russell, J. A. and Walley, K. R. (2003) Genetic polymorphisms in sepsis and septic shock:role in prognosis and potential for therapy. Chest 124, 1103-1115.
46. Hughes, A. K.; Stricklett, P. K. and Kohan, D. E. (1998) Cytotoxic effect of shiga toxin-1 on human proximal tubule cells. Kidney Int. 54, 426-437.
47. 2-adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension. Circulation 106, 349-355.
48. Jaber, B. L. and Pereira, B. J. G. (1996) Inflammatory mediators in sepsis: rationale for extracorporeal therapies. Am. J. Kidney Dis. 28, S35-S49.
49. Jaber, B. L.; Madhumathi, R.; Daqing, G.; Vaidyanathapuram, S.; Perianayagam, M.C.; Freeman, R. B. and Pereira, B. J. (2004) Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine 25, 212-219.
50. 2-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 117, 18-24.
51. Josefsson, E.; Bergquist, J.; Ekman, R. and Tarkowski, A. (1996) Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology 88, 140-146.
52. Kaplan, B. S.; Meyers, K. E. and Schulman, S. L. (1998) The pathogeneis and treatment of hemolytic uremic syndrome. J. Am. Soc. Nephrol. 8, 1126-1133.
53. Kaplan, S. L. (1998) Bacteremia and septic shock in Textbook of Pediatric Infectious Diseases; 4th ed. Feigin, R. D. and Cherry, J. D., (Eds); W.B. Saunders: Philadelphia, pp. 807-820.
54. Kayama, E.; Yoshida, T.; Kodama, Y.; Matsui, T.; Matheson, J. M.; Luster, M. I. (1997) Proinflammatory cytokines and interleukin-6 in the renal response to bacterial endotoxin. Cytokine 9, 688-695.
55. Kikeri, D.; Pennel, J. P.; Hwang, K. H.; Jakob, J. I.; Richman, A. V. and Bourgigne, J. J. (1986) Endotoxemic acute renal failure in awake rats. Am. J. Physiol. 250, F1098-F1106.
56. Kim, F. J.; Moore, E. E. and Moore, F. A. (1994) Disparate signal transduction in neutrophil CD18 adhesion receptor expression versus superoxide generation. Surgery 116, 262-267.
57. Kiyokawa, N.; Taguchi, T.; Mori, T.; Uchida, H.; Sato, N.; Takeda, T. and Fujimoto, J. (1998) Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli shiga toxin 1 and 2. J. Infect. Dis. 178, 178-184.
58. Klahr, S. (1993) Interstitial macrophages. Semin. Nephrol. 13, 388-395.
59. Koepke, J. P. and Dibona, G. F. (1986). Central adrenergic receptor control of renal function in conscious hypertensive rats. Hypertension 8, 133-141.
60. Kohan, D. E. (1994) Role of endothelin and tumour necrosis factor in the renal response to sepsis. Nephrol. Dial. Transplant. 9, 73-77.
61. 2-adrenoceptor function. J. Clin. Invest. 100, 3005-3013.
62. Liano, F.; Junco, E.; Madero, R.; Pascual, J. and Verde, E. (1998) The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute renal Failure Study Group. Kidney Int. 66, S16-S24.
63. Liao, J.; Keiser, J. A.; Scales, W. E.; Kunkel, S. L. and Kluger, M. J. (1995) Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am. J. Physiol. 268, R896-R901.
64. 2-adrenergic receptor variants in asthma. Clin. Exp. Allergy 25, 89-94.
65. 2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med. 156, S156-S162.
66. Linas, S. L.; Whittenburg, D.; Parsons, P. E. and Repine, J. E. (1992) Mild renal ischemia activates primed neutrophils to cause acute renal failure. Kidney Int. 42, 610-616.
67. Lingwood, C. A. (1994) Verotoxin-binding in human renal sections. Nephron 66, 21-28.
68. 2-adrenoceptors in asthmatic patients. Chest 115, 324-328.
69. Lorenz, E.; Mira, J. P.; Frees, K. L. and Schwartz, D. A. (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162, 1028-1032.
70. Lowe, P. R.; Galley, H. F.; Abdel-Fattah, A. and Webster, N. R. (2003) Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit. Care Med. 31, 34-38.
71. Main, I. W.; Nikolic-paterson, D. J. and Atkins, R. C. (1992) T cells and macrophages and their role in renal injury. Semin. Nephrol. 12, 395-407.
72. Makhlouf, K.; Comabella, M.; Imitola, J.; Weiner, H. L. and Khoury, S. J. (2001) Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis. J. Neuroimmunol. 117, 156-165.
73. 2-AR genotype-related changes in cAMP levels in peripheral blood mononuclear cells after multiple-dose oral procaterol. Pharm. Res. 18, 1651-1654.
74. 2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals. Hypertens. Res. 30, 503-511.
75. s□ in septic rabbits. Anesthesiology 93, 1465-1473.
76. Meyer, U. A. (2000) Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671.
77. Mira, J. P.; Cariou, A.; Grall, F.; Delclaux, C.; Losser, M. R.; Heshmati, F.; Cheval, C.; Monchi, M.; Teboul, J. L.; Riché, F.; Leleu, G.; Arbibe, L.; Mignon, A.; Delpech, M. and Dhainaut, J. F. (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 282, 561-568.
78. 2-adrenergic receptor gene and desensitization in human airway smooth muscle. Am. J. Respir. Crit. Care Med. 162, 2117-2124.
79. 2-adrenoceptor in endotoxin-stimulated renal macrophage. Kidney Int. 56, 839-849.
80. 2-adrenoceptor agonist suppresses tumour necrosis factor production in rat mesangial cells. Cytokine 12, 491-484.
81. 2-adrenoceptor prevents shiga toxin-induced tumour necrosis factor production. J. Am. Soc. Nephrol. 12, 2288-2299.
82. 2-adrenoceptor activation inhibits Shiga toxin2-induced apoptosis of renal tubular epithelial cells. Biochem. Pharmacol. 266, 343-353.
83. 2-Adrenoceptor activation attenuates endotoxin-induced acute renal failure. J. Am. Soc. Nephrol. 15, 316-325.
84. Nakamura, M.; Yoshida, H.; Arakawa. N.; Saitoh, S.; Satoh, M. and Hiramori, K. (2000) Effects of tumor necrosis factor-α on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J. Cardiovasc. Pharmacol. 36, 487-492.
85. 2-adrenergic receptor in lymphocytes. Am. J. Respir. Crit. Care Med. 172, 322-328.
86. 2-Agonists prevent Th1 development by selective inhibition of interleukin 12. J. Clin. Invest. 100, 1513-1519.
87. Pinsky, M. R. (1998) The critically ill patient. Kidney Int. 53, S3-S6.
88. Pinsky, M. R.; Vincent, J. L.; Deviere, J.; Alegre, M.; Kahn, R. J. and Dupont, E. (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103, 565-575.
89. Pradervand, S.; Barker, P. M.; Wang, Q.; Ernst, S. A.; Beermann, F.; Grubb, B. R.; Burnier, M.; Schmidt, A.; Bindels, R. J.; Gatzy, J. T.; Rossier, B. C. and Hummler, E. (1999) Salt restriction induces pseudohypoaldosteronism type 1 in mice expressing low levels of the β-subunit of the amiloride-sensitive epithelial sodium channel. Proc. Natl. Acad. Sci. USA 96, 1732-1737.
90. 2-adrenergic receptor in normal and asthmatic subjects, Am. J. Respir. Cell Mol. Biol. 8, 334-339.
91. 2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J. Immunol. 158, 4200-4210.
92. 2-adrenoceptors. Crit. Care Med. 26, 1639-1645.
93. Schor, N. (2002) Acute renal failure and the sepsis syndrome. Kidney Int. 61, 764-776.
94. Severn, A.; Rapson, N. T.; Hunter, C. A. and Liew, F. Y. (1992) Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J. Immunol. 148, 3441-3445.
95. Shimkets, R. A.; Warnock, D. G.; Bositis, C. M.; Nelson-Williams, C.; Hansson, J. H. and Schambelan, M. (1994). Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell 79, 407-414.
96. 2 receptor agonist terbutaline. Am. J. Physiol. Imaging 4, 136-142.
97. Silverman, H. J.; Penaranda, R.; Orens, J. B. and Lee, N. H. (1993) Impaired β-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: Association with myocardial hyporesponsiveness to cathecholamines. Crit. Care Med. 21, 31-39.
98. 2-adrenoceptor function in cultured rat proximal tubular epithelial cells. Am. J. Physiol. 273, F193-F199.
99. 2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans. J. Physiol. 571, 121-130.
100. 2-adrenergic receptor and the natriuretic response to rapid saline infusion in humans. J. Physiol. 574, 947-954.
101. + channel to the cell surface. J. Clin. Invest. 105, 45-53.
102. Stone, R. (1994) Search for sepsis drugs goes on despite past failures. Science 264, 365-367.
103. 2. J. Exp. Med. 180, 2365-2370.
104. Stuber, F.; Petersen, M. and Bokelmann, F. (1996) A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor β concentrations and outcome of patients with severe sepsis. Crit. Care Med. 24, 381-384.
105. 2-AR stimulant, terbutaline. Acta Physiol. Scand. 101, 504-506.
106. Tago, K.; Schuster, V. L. and Stokes, J. B. (1986) Regulation of chloride self exchange by cAMP in cortical collecting tubule. Am. J. Physiol. 251, F40-F48.
107. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350, 995-999.
108. Tang, G. J.; Huang, S. L.; Yien, H. W.; Chen, W. S.; Chi, C. W.; Wu, C. W.; Lui, W. Y.; Chiu, J. H. and Lee, T. Y. (2000) Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit. Care Med. 28, 2733-2736.
109. Thijs, A. and Thijs, L. G. (1998) Pathogenesis of renal failure in sepsis. Kidney Int. 66, S34-S37.
110. 2-adrenergic stimulation. J. Neuroimmunol. 96, 131-143.
111. Tighe, D.; Moss, R. and Bennett, D. (1996) Cell surface adrenergic receptor stimulation modifies the endothelial response to SIRS. Systemic Inflammatory Response Syndrome. New Horiz. 4, 426-442.
112. 2 antagonist. Clin. Sci. (Lond). 95, 467-478.
113. Treszl, A.; Toth-Heyn, P.; Kocsis, I.; Nobilis, A.; Schuler, A.; Tulassay, T. and Vasarhelyi, B. (2002) Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr. Nephrol. 17, 713-717.
114. Tschaikowsky, K.; Sagner, S.; Lehnert, N.; Kaul, M. and Ritter, J. (2000) Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit. Care Med. 28, 1854-1860.
115. Uddman, E.; Moller, S.; Adner, M. and Edvinsson, L. (1999) Cytokines induce increased endothelin ET(B) receptor-mediated contraction. Eur. J. Pharmacol. 376, 223-232.
116. van de Kar, N. C.; Monnens, L. A.; Karmali, M. A. and van Hinsbergh, V. W. (1992) Tumour necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human vascular endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80, 2755-2764.
117. van der Poll, T. and Lowry, S. F. (1995) Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 3, 1-12.
118. van der Poll; Coyle, S. M.; Karen Barbosa, K.; Braxton, C. C. and Lowry, S. F. (1996) Epinephrine inhibits tumor necrosis factor- and potentiates interleukin-10 production during human endotoxemia. J. Clin. Invest. 97, 713-719.
119. 2 is a potent inhibitor of human interleukin -12 production. J. Exp. Med. 181, 775-779.
120. Vasarhelyi, B.; Toth-Heyn, P.; Treszl, A. and Tulassay, T. (2005) Genetic polymorphisms and risk for acute renal failure in preterm neonates. Pediatr. Nephrol. 20, 132-135.
121. Vicencio, A.; Bidmon, B.; Ryu, J.; Reidy, K.; Thulin, G.; Mann, A.; Gaudio, K. M.; Kashgarian, M. and Siegel, N. J. (2003) Developmental expression of HSP-72 and ischemic tolerance of the immature kidney. Pediatr. Nephrol. 18, 85-91.
122. Wallace, D. P.; Reif, G.; Hedge, A. M.; Thrasher, J. B. and Pietrow, P. (2004) Adrenergic regulation of salt and fluid secretion in human medullary collecting duct cells. Am. J. Physiol. 287, F639-F648.
123. Warren, H. S. (1997) Strategies for the treatment of sepsis. N. Engl. J. Med. 336, 952-953.
124. Warzocha, K.; Ribeiro, P. and Bienvenu, J. (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91, 3574-3581.
125. Waterer, G. W.; ElBahlawan, L.; Quasney, M. W.; Zhang, Q.; Kessler, L. A. and Wunderink, R. G. (2003) Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit. Care Med. 31, 1367-1372.
126. 2 adrenoceptors? J. Pharmacol. Exp. Ther. 278, 1105-1113.
127. Wiecek, A.; Zeier, M. and Ritz, E. (1994) Role of infection in the genesis of acute renal failure. Nephrol. Dial. Transplant. 9(Suppl. 4), 40-44.
128. Wilson, A. G.; Symons, J. A.; McDowell, T. L.; McDewitt, H. O. and Duff, G. W. (1997) Effects of a polymorphism in the human tumor necrosis factor promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA 94, 3195-3199.
129. 2 Adrenoceptor gene single nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden. Ann. Rheum. Dis. 64, 773-776.
130. Zager, R. A. (1986) Escherichia coli endotoxin injections potentiate experimental ischemic renal injury. Am. J. Physiol. 251, F988-F994.
131. Zhu, Y.; Prehn, J. H.; Culmsee, C. and Krieglstein, J. (1999) The beta2-adrenoceptor agonist clenbuterol modulates Bcl-2, Bcl-xl and Bax protein expression following transient forebrain ischemia. Neuroscience 90, 1255-1263.
132. Zoja, C.; Angioletti, S.; Donadelli, R.; Zanchi, C.; Tomasoni, S.; Binda, E.; Imberti, B.; Loo, M.; Monnens, L.; Remuzzi, G. and Morigi, M. (2002) Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 62, 846-856.